After a 27-month rollercoaster ride, can we expect a return to normal? 

Battered biotech is reviving after booming and busting in spectacular fashion. M&A is heating up as pharma companies face up to their patent cliff. And drug sales growth forecasts continue skyward. 

Big pharma had a smoother ride– not just relative to biotech, but as a defensive stalwart amid huge macro-economic pressures. Then of course there’s the unpredictability of China and a hard-to-read FDA to consider.

The Evaluate Pharma World Preview 2022 explores the future of the pharma and biotech landscape, based on Evaluate consensus forecasts out to 2028. 



The slow return of M&A as a patent cliff looms
Who’s up and who’s down in the global big pharma rankings?
What’s happening with gene and cell therapies?
What’s behind the heating up of the obesity market?